Progress in Intravenous Thrombolytic Therapy for Acute Stroke

Area of Science:

• Neurology
• Pharmacology
• Medical Imaging

Background:

• Intravenous recombinant tissue plasminogen activator (alteplase) has been the only FDA-approved treatment for acute ischemic stroke since 1996, despite limitations.
• Progress in thrombolytic therapy has been slow due to multifactorial reasons, including challenges in extending the treatment window and slow development of new drugs.

Purpose of the Study:

• To provide a historical overview of thrombolytic therapy for acute ischemic stroke.
• To examine current trends and future directions in stroke treatment, focusing on drug characteristics and clinical trials.

Main Methods:

• Review of pivotal clinical trials.
• Analysis of seminal articles on stroke physiology, pharmacology, and neuroimaging.
• Inclusion of data from clinical trial registries.

Main Results:

• Efforts to extend the therapeutic window for alteplase beyond 4.5 hours have been largely unsuccessful.
• Development of new thrombolytic drugs has been slow, with tenecteplase being a potential alternative.
• Advancements in catheter-based interventional revascularization have shifted focus from purely pharmacological studies.

Conclusions:

• Despite slow progress, advances in neuroimaging and combination therapy strategies are revitalizing the field of acute thrombolysis.
• New clinical trials combining thrombolytics with other treatments are gaining momentum.
• Emerging combination therapies hold promise for improving outcomes in acute ischemic stroke treatment.